Endo Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Endo Pharmaceuticals (Malvern, PA): 30 reconciled FDA prescription therapies (8.7% 2025 to 2030 cliff risk), $253.8M 2024 CMS Part D & Medicaid spend, and 78 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterMalvern, PA
Reconciled FDA Portfolio Therapies30
2025 to 2030 Patent-Cliff Revenue Exposure8.7%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$253.8M
2024 Medicare Part D Spend$190.6M
2024 Medicaid Spend$63.2M
California HCAI SB 17 Filings78 WAC filings (max 39.4% 2-yr change)